How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study.

IF 4 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-14 DOI:10.1080/14712598.2025.2545520

Sinan Işık, Selen Duygu Arık, Özlem Akgün, Vafa Guliyeva, Gülşah Kavrul Kayaalp, Şeyma Türkmen, Betül Sözeri, Nuray Aktay Ayaz

{"title":"How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study.","authors":"Sinan Işık, Selen Duygu Arık, Özlem Akgün, Vafa Guliyeva, Gülşah Kavrul Kayaalp, Şeyma Türkmen, Betül Sözeri, Nuray Aktay Ayaz","doi":"10.1080/14712598.2025.2545520","DOIUrl":null,"url":null,"abstract":"Objectives: Uveitis is a prevalent complication of juvenile idiopathic arthritis (JIA), leading to ocular morbidity. This study aimed to evaluate uveitis frequency in JIA patients on biologics and explore the impact of biologic selection on its occurrence.Methods: Among 2,385 JIA patients reviewed, 101 patients who developed uveitis were analyzed. This patients were categorized based on their uveitis development: under methotrexate, after discontinuation of methotrexate, and under biologics.Results: Uveitis frequency among all reviewed JIA patients was 6.3%. Among those who developed uveitis while receiving biologics, 30 were on etanercept and one on infliximab at the time of onset. When the entire cohort of JIA patients treated with biologics for joint symptoms was evaluated, it was observed that out of 365 patients using etanercept, uveitis developed in 30 individuals, in one out of 39 patients using infliximab, while no cases of uveitis were observed among 285 patients using adalimumab.Conclusion: In this study we observed a larger frequency of new onset uveitis in JIA patients treated with TNF receptor fusion proteins than those treated with anti-TNF monoclonal antibodies. Monoclonal anti-TNF-α agents may remain the preferred options. This study highlights the necessity of integrating uveitis risk assessment into JIA treatment strategies.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1025-1033"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2025.2545520","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Uveitis is a prevalent complication of juvenile idiopathic arthritis (JIA), leading to ocular morbidity. This study aimed to evaluate uveitis frequency in JIA patients on biologics and explore the impact of biologic selection on its occurrence.

Methods: Among 2,385 JIA patients reviewed, 101 patients who developed uveitis were analyzed. This patients were categorized based on their uveitis development: under methotrexate, after discontinuation of methotrexate, and under biologics.

Results: Uveitis frequency among all reviewed JIA patients was 6.3%. Among those who developed uveitis while receiving biologics, 30 were on etanercept and one on infliximab at the time of onset. When the entire cohort of JIA patients treated with biologics for joint symptoms was evaluated, it was observed that out of 365 patients using etanercept, uveitis developed in 30 individuals, in one out of 39 patients using infliximab, while no cases of uveitis were observed among 285 patients using adalimumab.

Conclusion: In this study we observed a larger frequency of new onset uveitis in JIA patients treated with TNF receptor fusion proteins than those treated with anti-TNF monoclonal antibodies. Monoclonal anti-TNF-α agents may remain the preferred options. This study highlights the necessity of integrating uveitis risk assessment into JIA treatment strategies.

查看原文本刊更多论文

治疗选择如何影响葡萄膜炎ın青少年特发性关节炎的发病和结局：一项回顾性队列研究。

目的：葡萄膜炎是青少年特发性关节炎（JIA）的常见并发症，导致眼部疾病。本研究旨在评价生物制剂对JIA患者葡萄膜炎发生率的影响，探讨生物选择对其发生的影响。方法：在2385例JIA患者中，对101例发生葡萄膜炎的患者进行分析。这些患者根据其葡萄膜炎的发展情况进行分类：甲氨蝶呤治疗组、甲氨蝶呤停药组和生物制剂组。结果：JIA患者葡萄膜炎发生率为6.3%。在接受生物制剂治疗时发生葡萄膜炎的患者中，30人在发病时服用依那西普，1人服用英夫利昔单抗。当整个队列的JIA患者接受生物制剂治疗关节症状进行评估时，观察到365例使用依那西普的患者中有30例出现葡萄膜炎，39例使用英夫利昔单抗的患者中有1例出现葡萄膜炎，而285例使用阿达木单抗的患者中没有出现葡萄膜炎。结论：在本研究中，我们观察到TNF受体融合蛋白治疗的JIA患者新发葡萄膜炎的频率高于抗TNF单克隆抗体治疗的患者。单克隆抗tnf -α药物可能仍然是首选的选择。本研究强调了将葡萄膜炎风险评估纳入JIA治疗策略的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.